美国目前已经进入临床阶段的在研肺癌药物一览

PhRMA全称为The Pharmaceutical Research and Manufacturers of America(美国药物研究和制造商协会)，是全球知名的药品研究与制造商协会，总部设在华盛顿，由美国领先的制药和生物技术研究公司组成，致力于发明新的药物，使患者的存活时间更长，更健康，更具生活质量。公司的主要任务是作为集体参与美国医药公共政策的制定，对医药行业争取利润空间，同时对医药政策进行宣传。

资料来源是PhRMA发布的2014 Cancer report，提取了其中关于肺癌的在研药品信息：

产品名称(Product Name)	制造商(Sponsor)	适应症(Indication)	在研阶段(Development Phase)
abemaciclib (CDK 4/6 inhibitor)	Lilly Indianapolis, IN	non-small-cell lung cancer (NSCLC) (see also breast, lymphoma)	Phase I www.lilly.com
ABT-RTA-408	AbbVie North Chicago, IL Reata Pharmaceuticals Irving, TX	metastatic NSCLC (see also skin)	Phase I www.abbvie.com www.reatapharma.com
ADI-PEG 20 (PEG arginine deiminase)	Polaris Pharmaceuticals San Diego, CA	small-cell lung cancer (SCLC) (see also breast, leukemia, liver, lymphoma, skin) -------------------------------- mesothelioma, NSCLC	Phase II www.polarispharma.com -------------------------------- Phase I www.polarispharma.com
Afinitor® everolimus	Novartis Pharmaceuticals East Hanover, NJ	neuroendocrine lung tumors (see also breast, lymphoma, stomach)	Phase III www.novartis.com
aldoxorubicin (delivery-enhanced doxorubicin)	CytRx Los Angeles, CA	SCLC (see also brain, sarcoma)	Phase II www.cytrx.com
alectinib (ALK inhibitor)	Chugai Pharma USA Berkeley Heights, NJ Roche Basel, Swizterland	NSCLC (Breakthrough Therapy)	Phase II www.chugai-pharm.com www.roche.com
alisertib (auroura A kinase inhibitor)	Millennium Pharmaceuticals Cambridge, MA	SCLC (see also lymphoma, ovarian)	Phase II www.millennium.com
antroquinonol	Golden Biotechnology New Taipei City, Taiwan	NSCLC	Phase II www.goldenbiotech.com.tw
AP26113 (ALK inhibitor)	ARIAD Pharmaceuticals Cambridge, MA	NSCLC	Phase II www.ariad.com
apatorsen (Hsp27 inhibitor)	OncoGenex Pharmaceuticals Bothell, WA	non-squamous NSCLC, squamous NSCLC (see also bladder, pancreatic, prostate)	Phase II www.oncogenex.com
ASP8273	Astellas Pharma US Northbrook, IL	NSCLC	Phase I/II www.astellas.com
AT13387 (HSP90 inhibitor)	Astex Pharmaceuticals Dublin, CA	NSCLC (see also skin)	Phase II www.astx.com
Avastin® bevacizumab	Genentech South San Francisco, CA	NSCLC (adjuvant) (see also brain, ovarian, other)	Phase III www.gene.com
AZD9291 (EGFR tyrosine kinase inhibitor)	AstraZeneca Wilmington, DE	advanced T790M mutation-positive NSCLC (Breakthrough Therapy)	Phase II/III www.astrazeneca.com
bavituximab	Peregrine Pharmaceuticals Tustin, CA	NSCLC (2nd-line) (see also breast, liver, skin, other) -------------------------------- NSCLC (1st-line)	Phase III www.peregrineinc.com -------------------------------- Phase I www.peregrineinc.com
BBI608 (cancer stemness kinase inhibitor)	Boston Biomedical Cambridge, MA	NSCLC (see also breast, colorectal, ovarian, skin, stomach)	Phase I/II www.bostonbiomedical.com
belinostat	Spectrum Pharmaceuticals Henderson, NV	NSCLC	Phase I/II www.sppirx.com
bevacizumab biosimilar	Actavis Parsippany, NJ Amgen Thousand Oaks, CA	NSCLC	Phase III www.actavis.com www.amgen.com
BIND-014 (PSMA-targeted docetaxel)	BIND Therapeutics Cambridge, MA	NSCLC (see also prostate)	Phase II www.bindtherapeutics.com
CRS-207 (cancer immunotherapy)	Aduro BioTech Berkeley, CA	mesothelioma (combination therapy) (see also pancreatic)	Phase I ww.adurobiotech.com
custirsen (OGX-111) (antisense oligonucleotide)	OncoGenex Pharmaceuticals Bothell, WA Teva Pharmaceutical Frazier, PA	NSCLC (Fast Track) (see also prostate)	Phase III www.oncogenex.com www.tevapharm.com
Cynviloq™ paclitaxel polymeric micelle for injection	Sorrento Therapeutics San Diego, CA	NSCLC (see also bladder, breast, ovarian, pancreatic)	Phase III www.sorrentotherapeutics.com
Cyramza® ramucirumab	Lilly Indianapolis, IN	NSCLC (combination therapy) (see also bladder, breast, colorectal, liver, ovarian, solid tumors, stomach)	Phase III www.lilly.com
CYT-6091 (nanomedicine)	CytImmune Sciences Rockville, MD	NSCLC (2nd-line)	Phase II www.cytimmune.com
dacomitinib (pan-HER inhibitor)	Pfizer New York, NY	EGFR-mutant NSCLC (1st-line) (see also solid tumors)	Phase III www.pfizer.com
DKN-01 (DKK1 protein inhibitor)	HealthCare Pharmaceuticals Cambridge, MA	NSCLC (see also myeloma, other)	Phase I www.healthcarepharmaceuticals.com
DPV-001 (toll-like receptor agonist)	UbiVac Portland, OR	NSCLC	Phase II www.ubivac.com
E7080 (multi-targeted kinase inhibitor)	Eisai Woodcli Lake, NJ	NSCLC (3rd-line monotherapy), NSCLC (RET translocations) (see also brain, liver, skin, other)	Phase II www.eisai.com
EGF816 (EGFR TK inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	NSCLC	Phase I/II www.novartis.com
ficlatuzumab (HGF/c-MET inhibitor)	AVEO Oncology Cambridge, MA	NSCLC	Phase II www.aveooncology.com
foretinib (c-MET kinase inhibitor)	GlaxoSmithKline Research Triangle Park, NC	NSCLC	Phase II www.gsk.com
ganetespib (Hsp90 inhibitor)	Synta Pharmaceuticals Lexington, MA	NSCLC (Fast Track) (see also breast, leukemia, ovarian)	Phase III www.syntapharma.com
GI-4000 (natural killer cell stimulant)	GlobeImmune Louisville, CO	NSCLC (see also pancreatic)	Phase II www.globeimmune.com
GL-ONC1 (oncolytic virus immunomodulator)	Genelux San Diego, CA	lung, malignant mesothelioma (see also head/neck, solid tumors, other)	Phase I www.genelux.com
GSK2879552 (LSD1/CoREST inhibitor)	GlaxoSmithKline Research Triangle Park, NC	relapsed/refractory SCLC	Phase I www.gsk.com
Halaven® eribulin	Eisai Woodcli Lake, NJ	NSCLC (see also breast, sarcoma)	Phase III www.eisai.com
Imprime PGG® intravenous immunostimulant	Biothera Eagan, MN	metastatic NSCLC (1st-line) (see also colorectal, leukemia, lymphoma, pancreatic)	Phase II www.biothera.com
INCB24360 (IDO1 inhibitor)	Incyte Wilmington, DE	NSCLC (see also ovarian, skin, other)	Phase I/II www.incyte.com
INCB39110 (JAK1 inhibitor)	Incyte Wilmington, DE	NSCLC (see also solid tumors)	Phase I/II www.incyte.com
ISIS-EIF4ERX (antisense oligonucleotide)	Isis Pharmaceuticals Carlsbad, CA	NSCLC (see also prostate)	Phase II www.isispharm.com
Jakafi® ruxolitinib	Incyte Wilmington, DE	NSCLC (see also breast, colorectal, pancreatic, other)	Phase I www.incyte.com
KD019 (TKI inhibitor)	Kadmon Pharmaceuticals Warrendale, PA	NSCLC (see also breast) -------------------------------- Src-positive NSCLC	Phase II www.kadmon.com -------------------------------- Phase I www.kadmon.com
KD032 (Ras antagonist)	Kadmon Pharmaceuticals Warrendale, PA	NSCLC (see also colorectal, pancreatic)	Phase II www.kadmon.com
Keytruda® pembrolizumab	Merck Whitehouse Station, NJ	NSCLC (see also bladder, breast, head/neck, hematological, kidney, myeloma, stomach)	Phase III www.merck.com
Kyprolis® car lzomab	Onyx Pharmaceuticals South San Francisco, CA	SCLC (see also myeloma)	Phase II www.onyx.com
lifastuzumab vedotin (anti-NaPi2b antibody drug conjugate) (RG7599)	Genentech South San Francisco, CA	NSCLC (see also ovarian)	Phase I www.gene.com
lucitanib (FGFR/VEGFR/PDGFR inhibitor)	Clovis Oncology Boulder, CO	squamous NSCLC (see also breast)	Phase II www.clovisoncology.com
lung cancer DNA vaccine (IC 1001)	Immune Cell Therapy Chicago, IL	NSCLC	Phase I www.immcellther.com
LY2510924 (CXCR4 peptide antagonist)	Lilly Indianapolis, IN	SCLC (see also kidney)	Phase II www.lilly.com
LY2875358 (c-Met mAb)	Lilly Indianapolis, IN	NSCLC (see also stomach)	Phase II www.lilly.com
LY2940680 (hedgehog/SMO antagonist)	Lilly Indianapolis, IN	SCLC	Phase I/II www.lilly.com
MAGE-A3 immunotherapeutic (recombinant antigen-speci c cancer immunotherapeutic)	GlaxoSmithKline Research Triangle Park, NC	NSCLC	Phase III www.gsk.com
ME-344 (mitochondrial inhibitor)	MEI Pharma San Diego, CA	SCLC (see also ovarian)	Phase I www.meipharma.com
MEDI4736 (anti-PD-L1 mAb)	MedImmune Gaithersburg, MD	stage III NSCLC, NSCLC (3rd-line)	Phase III www.medimmune.com
MEDI4736 + Iressa® gefitinib (anti-PD-L1 mAb/EGFR inhibitor)	MedImmune Gaithersburg, MD	NSCLC	Phase I www.medimmune.com
MGCD265 (MET/Axl/VEGFR kinase inhibitor)	Mirati Therapeutics San Diego, CA	NSCLC (see also head/neck)	Phase I www.mirati.com
MM-121 (ErbB-3 receptor antagonist)	Merrimack Pharmaceuticals Cambridge, MA	NSCLC (see also breast, ovarian)	Phase II www.merrimackpharma.com
MORAb-003 (IgG1 mAb)	Eisai Woodcli Lake, NJ Morphotek Exton, PA	NSCLC (see also ovarian)	Phase II www.eisai.com
MORAb-009 (megakaryocyte potentiating factor inhibitor) ORPHAN DRUG	Eisai Woodcli Lake, NJ Morphotek Exton, PA	mesothelioma -------------------------------- solid tumors	Phase II www.eisai.com -------------------------------- Phase I www.eisai.com
NC-6004 (nanoparticle cisplatin)	NanoCarrier Tokyo, Japan	NSCLC	Phase I/II www.nanocarrier.co.jp
necitumumab (EGFR inhibitor)	Lilly Indianapolis, IN	squamous NSCLC	Phase III www.lilly.com
nivolumab (PD-1 inhibitor)	Bristol-Myers Squibb Princeton, NJ	NSCLC (1st-line), squamous NSCLC (2nd-line), non-squamous NSCLC (2nd-line) (see also brain, colorectal, head/neck, hematological, kidney, liver, lymphoma, skin, solid tumors) -------------------------------- squamous NSCLC (3rd-line) -------------------------------- NSCLC, SCLC	Phase III www.bms.com -------------------------------- Phase II www.bms.com -------------------------------- Phase II www.bms.com
nivolumab + Yervoy® ipilimumab	Bristol-Myers Squibb Princeton, NJ	NSCLC, SCLC (see also brain, colorectal, head/neck, hematological, kidney, skin)	Phase I www.bms.com
patritumab (anti-HER3 antibody)	Daiichi Sankyo Parsippany, NJ	NSCLC (see also breast)	Phase II www.dsi.com
PDT with Photofrin® porfimer sodium ORPHAN DRUG	Pinnacle Biologics Bannockburn, IL	epithelioid malignant pleural mesothelioma (see also liver)	Phase III www.pinnaclebiologics.com
pelareorep	Oncolytics Biotech Calgary, Canada	NSCLC, squamous cell carcinoma of the lung (see also colorectal, head/neck, myeloma, ovarian, pancreatic, skin, solid tumors, other)	Phase II www.oncolyticsbiotech.com
pictrelisib (PI3K inhibitor)	Genentech South San Francisco, CA	metastatic NSCLC (see also breast)	Phase II www.gene.com
PRAME immunotherapeutic (recombinant antigen-specific cancer immunotherapeutic)	GlaxoSmithKline Research Triangle Park, NC	resectable NSCLC	Phase II www.gsk.com
PT 107 (allogeneic B7.1/HLA-A1 transfected tumor cell vaccine)	Pique Therapeutics Durham, NC	NSCLC	Phase II www.piquetherapeutics.com
RG7446 (anti-PD-L1 mAb)	Genentech South San Francisco, CA	NSCLC (2nd-line) (see also bladder, kidney, skin) -------------------------------- NSCLC (3rd-line) -------------------------------- EGFR-positive NSCLC	Phase III www.gene.com -------------------------------- Phase II www.gene.com -------------------------------- Phase I www.gene.com
rociletinib (CO-1686) (EGFR inhibitor)	Clovis Oncology Boulder, CO	EGFR-mutated NSCLC (Breakthrough Therapy)	Phase II www.clovisoncology.com
roniciclib (CDK inhibitor)	Bayer HealthCare Pharmaceuticals Whippany, NJ	SCLC	Phase II www.bayerpharma.com
sapacitabine ORPHAN DRUG	Cyclacel Pharmaceuticals Berkeley Heights, NJ	NSCLC (see also hematological, leukemia)	Phase II www.cyclacel.com
SC16LD6.5 (antibody drug conjugate)	Stem CentRx South San Francisco, CA	SCLC	Phase I/II www.stemcentrx.com
seliciclib (CDK inhibitor)	Cyclacel Pharmaceuticals Berkeley Heights, NJ	NSCLC (see also other)	Phase II www.cyclacel.com
selumetinib (MEK inhibitor)	Array BioPharma Boulder, CO AstraZeneca Wilmington, DE	KRAS-positive NSCLC (2nd-line) (see also other) -------------------------------- KRAS-negative NSCLC (2nd-line)	Phase III www.arraybiopharma.com www.astrazeneca.com -------------------------------- Phase III www.arraybiopharma.com www.astrazeneca.com
SPI-1620 (endothelin B receptor agonist)	Spectrum Pharmaceuticals Henderson, NV	NSCLC (see also liver)	Phase II www.sppirx.com
Tafinlar® dabrafenib	GlaxoSmithKline Research Triangle Park, NC	NSCLC (Breakthrough Therapy)	Phase II www.gsk.com
tarextumab (anti-NOTCH 2/3)	OncoMed Pharmaceuticals Redwood City, CA	SCLC (see also pancreatic)	Phase I/II www.oncomed.com
Tavocept™	BioNumerik Pharmaceuticals San Antonio, TX	lung cancer	Phase III www.bionumerik.com
tergenpumatucel-L	NewLink Genetics Ames, IA	advanced or metastatic NSCLC	Phase II/III www.newlinkgenetics.com
TG4010 (MVA-MUC1-IL2 cancer vaccine)	Transgene Cambridge, MA	advanced NSCLC	Phase II/III www.transgene.fr
TH-302 (hypoxia-activated prodrug)	EMD Serono Rockland, MA Threshold Pharmaceuticals South San Francisco, CA	NSCLC (see also hematological, pancreatic, skin, sarcoma, solid tumors)	Phase II www.emdserono.com www.thresholdpharm.com
topotecan liposomal	Spectrum Pharmaceuticals Henderson, NV	lung cancer (see also breast)	Phase I www.sppirx.com
tremelimumab (anti-CTLA-4 mAb)	MedImmune Gaithersburg, MD	mesothelioma	Phase III www.medimmune.com
tremelimumab (anti-CTLA-4 mAb)/Iressa® ge tinib combination	AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD	NSCLC	Phase I www.astrazeneca.com www.medimmune.com
TSR-011 (ALK/TRK inhibitor)	TESARO Waltham, MA	NSCLC	Phase I/II www.tesarobio.com
TUSC2 (gene therapy)	Genprex Austin, TX	NSCLC	Phase I/II www.genprex.com
Vargatef™ nintedanib	Boehringer Ingelheim Pharmaceuticals Ridge eld, CT	NSCLC (see also ovarian) -------------------------------- mesothelioma	Phase III www.boehringer-ingelheim.com -------------------------------- Phase II www.boehringer-ingelheim.com
veliparib	AbbVie North Chicago, IL	NSCLC (see also brain, breast)	Phase III www.abbvie.com
viagenpumatucel-L (cancer immunotherapy)	Heat Biologics Durham, NC	NSCLC	Phase II www.heatbio.com
vinorelbine liposomal	Spectrum Pharmaceuticals Henderson, NV	SCLC (see also ovarian)	Phase I www.sppirx.com
vintafolide (folate-DAVLBH)	Endocyte West Lafayette, IN	NSCLC (see also solid tumors)	Phase II www.endocyte.com
VS-6063 (FAK inhibitor) ORPHAN DRUG	Verastem Cambridge, MA	KRAS-mutant NSCLC, mesothelioma (see also ovarian)	Phase II www.verastem.com
Xalkori® crizotinib ORPHAN DRUG	Pfizer New York, NY	ALK-positive NSCLC (1st-line) (see also solid tumors)	Phase III www.pfizer.com
Xgeva® denosumab	Amgen Thousand Oaks, CA	metastatic NSCLC (1st-line) (see also breast)	Phase II www.amgen.com
Yervoy® ipilimumab	Bristol-Myers Squibb Princeton, NJ	SCLC (1st-line), squamous NSCLC (1st-line) (see also ovarian, prostate, skin, stomach)	Phase III www.bms.com
Zykadia™ ceritinib	Novartis Pharmaceuticals East Hanover, NJ	ALK-positive advanced NSCLC (1st-line, treatment naïve)	Phase II www.novartis.com

source: http://www.phrma.org/sites/defau ... 4-cancer-report.pdf

感谢costa_na！我们又看到希望啦{:soso_e100:}

{:soso_e160:} 谢谢COAST分享 期待ING

这得多少药，如果大都能轮换有效的话，病友有福了。

不知有多少药能有明显的作用。

这仅是美国的吗？那么我想其他国家是不是应该也会有一些，希望能早日研发出有效的药物

网上找的几个fast track和 breakthrough 药的简单介绍。

AZD9291 就不说了，帖子已经很多了。

Dabrafenib (trade name Tafinlar) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.[1][2]

The Food and Drug Administration approved dabrafenib as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma on May 30, 2013.[3] Clinical trial data demonstrated that resistance to dabrafinib and other BRAF inhibitors occurs within 6 to 7 months.[4] To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib.[4] As a result of this research, on January 8, 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma.[5]

Rociletinib (CO-1686) is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). Rociletinib was designed to selectively target both the initial activating EGFR mutations and the T790M resistance mutation, while sparing wild-type, or normal EGFR at anticipated therapeutic doses, with an improved toxicity profile. Accordingly, it has the potential to be a first-line treatment in NSCLC patients with activating EGFR mutations and a second or later-line treatment in NSCLC patients who become resistant to EGFR-directed therapy due to the emergence of the T790M secondary mutation.

ganetespib
A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of "client" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors. Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

custirsen sodium 化疗药物
The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

alectinib
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

谢谢分享~呵呵

英文的看不懂，有中文就好了，但还是好消息

AP26113，想说爱你不容易！要多少米，才能拥有你！！！